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Abstract
Background: The administration of non-antifungal drugs during patient hospitalization might be
responsible for discrepancies between in vitro and in vivo susceptibility to antifungals. Propofol is
often administered to intensive care units as a sedative.
The purpose of this study was to evaluate the effect of propofol lipidic infusion upon the growth
and susceptibility profile of pathogenic fungi.
Candida and Aspergillus were studied regarding the ability to grow and its susceptibility profile to
antifungals in the presence of propofol infusion (Fresenius®) (1.25, 2.5 and 5 mg.ml-1) and its lipidic
vehicle. The intensity of fluorescence after staining with FUN1, in the presence and absence of
propofol infusion, was determined by flow cytometry. Radioactivity assays were also performed in
order to quantify the input of [3H]- itraconazole into the fungal cell in the presence of propofol.
Assays were repeated after addition of sodium azide, in order to block efflux pumps.
Results: Propofol infusion promoted budding of Candida and the germination of Aspergillus, latter
forming a lipid layer around the hypha. An increase of minimal fungicidal concentrations regarding
both Candida and Aspergillus strains was found for all antifungals when incubated simultaneously with
propofol infusion. A decrease of the intensity of fluorescence of Candida cells was systematically
observed, as well as a significant reduced intracellular uptake of [3H] itraconazole in cells treated
with propofol infusion, even after the blockade of efflux pumps. The results obtained when testing
with the lipid vehicle were similar.
Conclusion: Propofol infusion, due to its lipidic vehicle, increased the fungal germination and
promoted resistance to antifungals. This effect seems to be related to the reduced access and/or
permeabilization to fungal cells by antifungals.
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Background
Discrepancies between in vivo and in vitro susceptibility to
antifungals discourage microbiologists and clinicians
regarding the routine use of susceptibility testing meth-
ods. Although in vitro resistance usually correlates with
clinical resistance, high susceptibility in vitro is not always
related to clinical success, particularly for Aspergillus spp.,
most strains being susceptible in vitro [1]. Ultimately, the
mortality rates are unacceptably high in patients treated
with antifungals that showed high in vitro efficacy [1,2].
Propofol is an intravenous hypnotic agent very popular
for induction and maintenance of general and intrave-
nous anaesthesia. It is commonly administered in Inten-
sive Care Units to critically ill patients, often under
mechanical ventilation, which represent a high risk group
for health care related infections. The use of propofol has
been previously associated to an increased risk for infec-
tion, although some controversy still remains [3,4]. It was
proposed a low risk of contamination whenever provid-
ing standard hygienic precautions [3,5]. Nevertheless,
other observations described the lipid emulsion of propo-
fol as a good culture medium to support the growth of
Candida albicans and Escherichia coli [6,7]. Additionally,
other reports associated post surgical infections with the
extrinsically contamination of propofol infusion [5,8].
Propofol has also been shown to inhibit a variety of func-
tions of neutrophils in vitro, although such effect was not
so evident in vivo [9].
We have studied the effect of the infusion of propofol and
its lipidic vehicle upon antifungal susceptibility of Cand-
ida and Aspergillus spp. A promotion of resistance due to a
decreased input of the antifungal drugs was found.
Results
In  Candida  strains, budding and germ tube formation
were similar in presence of all tested concentrations of
propofol infusion. In non-albicans strains, the incubation
with 5 μg.ml-1 of propofol infusion resulted in a signifi-
cant increased of cells with buds when comparing to con-
trol (71.5% ± 7.46 versus 26.6% ± 4.15, C. parapsilosis n =
5 as a representative example) (p < 0.001). Conversely, a
significant reduction of germ tube formation was
observed in C. albicans strains comparing with non-
treated yeasts (17.3% ± 6.29, versus 76.2% ± 8.69, n = 5)
(p < 0.001). Aspergillus conidia germinated in RPMI 1640
culture medium after 4 to 6 hours, the hyphal form being
obtained following 10 to 12 hours. Propofol infusion
supported the germination of all Aspergillus strains, show-
ing similar values to those obtained in plain RPMI 1640
medium. A significantly higher percentage of germination
of A. fumigatus conidia was found in PBS plus propofol
and plain propofol infusion in comparison with plain
PBS (21% ± 3.6 versus 6% ± 1.6, n = 5) (p = 0.047) follow-
ing 6 hours at 37°C. Longer incubation periods of conidia
with propofol infusion showed lipidic drops or a lipidic
layer around the hypha, in all assays and with all strains,
which remained present following several washings steps
(Figure 1).
The result of MIC determination revealed that all fungal
strains were susceptible to the tested antifungals. Propofol
infusion or its vehicle, at the tested concentrations, con-
sistently promoted an increase of MFC mean values for
Candida and Aspergillus strains(Table 1), this effect being
dose-dependent and statistically significant (p < 0.001);
such effect was invariably observed with all strains of Can-
dida and Aspergillus and with all antifungals, in some cases
the mean values increasing over 4 fold. MFC values in the
presence of 5 mg.ml-1 of propofol infusion or its vehicle
increased at least 2 dilutions in all strains (above the error
rate of the method) for fluconazole and voriconazole,
more than 3 dilutions for amphotericin B and 4 to 5 dilu-
tions for posaconazole and itraconazole. There was no
large variability between the tested strains.
Flow cytometry analysis of Candida blastoconidia resulted
in 98% of cells stained with FUN1, even after the incuba-
tion of sodium azide (Figure 2b). However, after treat-
ment with propofol infusion and stained with FUN1, a
non-stained sub-population of cells, similar to autofluo-
rescence, of around 15% was revealed soon after 90 min-
utes (Figure 2c). This fact was unrelated with the
incubation with sodium azide at a concentration able to
block the efflux pumps (Figure 2c). The azole resistant
strain of C. albicans 95–190 (with overexpression of efflux
pumps genes), after treatment with propofol infusion and
stained with FUN1, revealed a non-stained sub-popula-
tion, similar to other susceptible strains, even after the
blockade of the efflux pumps with sodium azide. This
effect was similar in presence of all the tested concentra-
tions of propofol.
After 1 hour, the accumulation of [3H]-labelled itracona-
zole was detected in blastoconidia cells (control cells)
(Figure 3). However, a decrease of 39% in intracellular
[3H]-labelled itraconazole was seen when yeast cells were
incubated with propofol lipid infusion (Figure 3). This
effect was similar in presence of the different tested con-
centrations of propofol lipidic infusion and did not
increase following the pre-incubation with sodium azide
(Figure 3).
The results obtained in the different assays were similar
when performed with propofol lipidic vehicle.
Discussion
Propofol administered in a lipid-based emulsion to
patients has been shown to represent an excellent vehicle
for supporting the growth of various microorganismsBMC Microbiology 2008, 8:9 http://www.biomedcentral.com/1471-2180/8/9
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[6,7]. In the present study we clearly showed that budding
of Candida  spp. was promoted when incubated in the
presence of propofol infusion, significantly more than in
a culture medium. Aspergillus fumigatus germinate faster
than the other Aspergillus species, possibly being associ-
ated to higher pathogenicity [10]. We showed that propo-
fol infusion also supported mould germination and
growth, apart from yeasts. It is important to emphasize
that the propofol concentrations used in all assays are
within the plasma levels often achieved in clinical practice
[11,12].
Due to the opacity of propofol infusion or its lipidic vehi-
cle it was not possible to determine MIC values. As the
conventional susceptibility phenotypes refer to MIC val-
ues, we could not establish the corresponding phenotypes
after incubation with propofol. In the case of amphoter-
icin B (a fungicidal drug to both Candida and Aspergillus)
MFC, determined after culture in agar solid medium, usu-
ally corresponds to MIC values; for the other antifungals,
MFC values are usually located within one or three dilu-
tions above the MIC. Some C. albicans and C. tropicalis
showed trailing phenotype (about 2 dilutions) for azoles.
This common effect may influence the evaluation of MFC
values. However, trailing is only azole dependent and was
not affected by the presence of propofol infusion. Never-
theless, we could observe a significant promotion of the
MFC value in presence of propofol infusion, in some cases
up to 4 dilutions, suggesting that the strains became quite
tolerant to the effect of all antifungals. FUN1 is a fluores-
cent probe that is converted by metabolically active yeasts
in intracytoplasmic vacuolar structures [13]. We have used
this probe to study susceptibility of yeasts after incubation
during one to two-hours with the antifungals; a higher
intensity of fluorescent in susceptible strains, decreasing
in resistant strains was described [14,15]. The decrease of
the intensity of fluorescence could be explained by the
presence of energy-dependent efflux pumps, which were
reverted with sodium azide or several modulators [13,14].
In the present study, the viable cells showed a decrease of
Representative example of Aspergillus fumigatus, after 24 hours of incubation Figure 1
Representative example of Aspergillus fumigatus, after 24 hours of incubation: a. non-treated cells; b. cells treated with 5 mg.ml-
1 of propofol infusion; c. cells treated with 5 mg.ml-1 of propofol infusion and washed thrice in sterilized water. (h hypha; p1 lip-
idic layer around hypha; p2 lipidic drops).BMC Microbiology 2008, 8:9 http://www.biomedcentral.com/1471-2180/8/9
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the intensity of fluorescence in the presence of propofol
which was not however reverted with sodium azide, even
considering the resistant tested strain. Furthermore, cells
were washed several times before the addition of the fluo-
rescent probe in order to avoid its binding to propofol
infusion. These results support that propofol infusion
affected FUN1 access and/or permeabilization, reducing
the input of the fluorescent probe into the cell. We had
also previously shown that [3H]-labelled itraconazole
accumulation could be a useful tool to confirm the exist-
ence of efflux pumps in resistant Candida strains to azoles
[16]. The blockade of efflux pumps with sodium azide
resulted in the reduction of input of [3H]-labelled itraco-
nazole in Candida cells, after incubation with propofol
infusion. In fact, propofol infusion was responsible for
the difficult access of itraconazole to the fungal cell.
Attending to the facts that i) the increase of MFC values
was similar with all antifungal drugs, including the
recently available posaconazole; ii) FUN1 could not stain
a considerable percentage of the yeast cells in presence of
propofol infusion and iii) a lesser amount of [3H]-
labelled itraconazole was present within such cells, even
after the addition of sodium azide, we are forced to con-
clude that the promotion of antifungal resistance in pres-
ence of propofol lipidic infusion results from a reduced
access and/or permeabilization of antifungal agents into
the fungal cells. The same results were obtained when
only the propofol vehicle was used, thus we had con-
cluded that the major responsible for such effect was the
lipidic nature of propofol infusion. The formation of a lip-
idic layer surrounding the cells supports such assumption,
being responsible for the reduced permeabilization. Sev-
eral studies reported that the lipidic membrane of fungal
cells plays an important role in susceptibility to azoles
[17,18]. Fluctuations in the lipidic environment affects,
not only drug diffusion but also efflux pumps, coded spe-
cially by Cdr1 and Pdr5p, leading to multidrug azole
Table 1: Minimal fungicidal concentration (MFC) values of Candidaand Aspergillus strains to AMB (amphotericin B), FLC (fluconazole), 
ITC (itraconazole), VRC (voriconazole) and PSC (posaconazole), determined by CLSI protocols, in the absence and presence of 
propofol infusion
Strains (n)
MFC values* range μg.ml-1
Antifungals Propofol(mg.ml-1) C. albicans (5) C. tropicalis (5) C. parapsilosis (5) C. glabrata (5) A. fumigatus (5) A. flavus (4) A. niger (4)
AMB 0 0.25 0.25–1 0.06–0.125 0.25–0.5 0.25–0.5 0.5–1 0.06–0.25
1.25 0.5–1 1 2 2 1–4 1–>16 0.25–1
2.5 0.5–2 1–2 2 2 2–4 1–>16 0.25–1
5 2–4 2 2–8 4–8 4–16 4–>16 0.5–2
FLC 0 8–16 4–8 8–16 16 nd nd nd
1.25 16–>64 >64 >64 >64 nd nd nd
2.5 16–>64 >64 >64 >64 nd nd nd
5 16–>64 >64 >64 >64 nd nd nd
ITC 0 nd nd nd nd 0.5–16 0.125–0.25 0.125–16
1.25 nd nd nd nd >16 2–>16 >16
2.5 nd nd nd nd >16 8–>16 >16
5 nd nd nd nd >16 16–>16 >16
VRC 0 0.06–0.25 0.25–0.5 0.5–1 4–8 0.25–4 0.25–2 0.06–8
1.25 0.25–>2 >2 >2 >8 2–8 0.25–2 1–16
2.5 0.5–>2 >2 >2 >8 2–8 0.5–4 1–16
5 1–>2 >2 >2 >8 2–8 0.5–4 1–16
PSC 0 0.06–0.125 0.03–0.125 0.06–0.125 1–2 0.03–0.25 0.03–0.06 0.06–1
1.25 1–2 >2 2 2 1–4 0.25–2 0.125–8
2.5 >2 >2 2 >2 1–4 0.5–2 0.25–16
5 >2 >2 >2 >2 1–4 0.5–4 0.25–>16
nd not done
* The mean value for each strain was consideredBMC Microbiology 2008, 8:9 http://www.biomedcentral.com/1471-2180/8/9
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resistance [19,20]. In our study, as the efflux pumps were
blocked with sodium azide, the increased MFC values
probably resulted from poor diffusion of the antifungal
drugs caused by the lipidic vehicle layer or drops depos-
ited around the cells. The hypothesis that propofol could
be binding the antifungal agent in culture medium reduc-
ing the free number of molecules available for penetrating
the cells was also raised. MFC results were more evident
when propofol was associated with itraconazole or posa-
conazole (increase of 4 to 5 dilutions), both lipophilic
drugs. However, we must consider that different concen-
trations of propofol resulted in similar effects. The
hypothesis that the lipidic vehicle of propofol might be
playing a role in sterol homeostasis and changing the
azole target, should be considered attending to other
research [21]. Lipid uptake by the fungal cell was
described in the presence of the azoles following longer
incubation time (overnight) [21]. Measuring sterols in
azole-treated fungi in the presence or not of the lipidic
vehicle of propofol could be interesting however, the
incubation time with propofol on cytometric and radioac-
tivity studies was very short to allow the incorporation of
the lipid in membrane.
Conclusion
The assays described in this manuscript provided an
opportunity to describe the effect of propofol infusion in
antifungal drug resistance. We concluded that propofol
infusion, due to its lipidic vehicle reduced the access and/
or permeabilization to Candida  and  Aspergillus  cells to
main antifungals administered to patients.
The described effect should raise the alert to a promoted
risk of fungal infections in patients receiving propofol
infusions, resulting from the fact that fungal strains
become increasingly resistant to antifungals.
Methods
Strains
Twenty clinical strains of Candida spp. (5 C. albicans, 5 C.
tropicalis, 5 C. glabrata and 5 C. parapsilosis) and thirteen
strains of Aspergillus spp.(5 A. fumigatus, 4 A. flavus and 4
A. niger) were studied. C. albicans 95–190, resistant to
azoles by overexpression of efflux pumps genes (CDR1
and CDR2), was used during cytometric approach (strain
Effect of propofol up on [3H]-labelled itraconazole accumula- tion in antifungal susceptible strain C. albicans ATCC 90028 Figure 3
Effect of propofol up on [3H]-labelled itraconazole accumula-
tion in antifungal susceptible strain C. albicans ATCC 90028. 
The accumulation of itraconazole was measured in the 
absence and presence of 5 mg.ml-1 of propofol and after a 
prior incubation with 0.1 mM sodium azide. Dispersion bars 
relates to standard deviation.
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Flow cytometric histograms representing the emitted fluorescence after 90 minutes by Figure 2
Flow cytometric histograms representing the emitted fluorescence after 90 minutes by: a. non-stained yeast cells (autofluores-
cence); b. cells treated with sodium azide and stained with FUN1; c. cells treated with sodium azide and 5 mg.ml-1 of propofol 
infusion and stained with FUN1 (strain of Candida albicans shown as a representative example).BMC Microbiology 2008, 8:9 http://www.biomedcentral.com/1471-2180/8/9
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kindly gift by Prof. Theodore White). Until testing, yeasts
and moulds were kept frozen in Brain-Heart broth (Difco
Laboratories, Detroit, MI, USA) with 5% glycerol. For each
experiment, the strains were subcultured twice on Sabour-
aud agar (Difco) at 35°C, 48 hours for Candida and 7 days
for Aspergillus.
Drugs and Chemicals
Propofol infusion Fresenius® (Kabi, France) at stock con-
centration of 1% was used. Propofol vehicle (soya bean
oil, egg lecithin, glycerol, sodium hydroxide and sterile
water) was also assayed. Fluconazole and voriconazole
were obtained from Pfizer (Groton, CT, USA), amphoter-
icin B from Bristol-Myers Squibb (New York, USA), itraco-
nazole from Janssen-Cilag (Beerse, Belgium) and
posaconazole from Shering-Plough (Kenilworth, NJ,
USA). Antifungals drugs were maintained in stock solu-
tion at -70°C until use. [3H]-labelled itraconazole was
supplied by Janssen-Cilag. Sodium azide was purchased
from Sigma (Sigma-Aldrich, Germany).
Growth assays
After cultivation of Candida and Aspergillus strains in Sab-
ouraud agar medium (Difco, Detroit, MI, USA), a 5 ×
106.ml-1 blastoconidia or conidia suspension of Candida
and Aspergillus was prepared in phosphate buffer saline
(PBS) (Sigma) and 100 μl were added in two parallel
serial dilutions of propofol infusion (stock solution at
1%) and its vehicle (both at 0, 1.25, 2.5 and 5 mg.ml-1
final concentrations) in RPMI 1640 culture medium
(Sigma), PBS and plain propofol infusion in a final vol-
ume of 500 μl. RPMI is a hydrophilic medium, however,
solubility problems were not found. For Candida strains,
samples were collected after 3 hours incubation at 37°C,
the cells were observed under phase contrast microscopy
(Leitz Larborlux K) and the percentage of budding and
germ tube formation (for C. albicans) were determined
[22]. For Aspergillus, the percentage of conidial germina-
tion was determined after incubation for 6, 12 and 24
hours at 37°C [10].
Susceptibility testing
For Candida spp., the minimal inhibitory concentration
(MIC) to fluconazole, voriconazole, posaconazole and
amphotericin B (tested concentration range: 0.125–64
μg.ml-1, 0.03–16 μg.ml-1, 0.03–16 μg.ml-1 and 0.03–16
μg.ml-1, respectively) were determined accordingly the
CLSI protocols M27-A2 (formerly NCCLS) [23]. Strains
were classified as susceptible (S), susceptible-dose
dependent (S-DD) and resistant (R) to fluconazole
according to breakpoints defined by CLSI [23]. For vorico-
nazole MICs ≤ 1 μg.ml-1 were considered S, MIC = 2 μg.ml-
1 considered S-DD and MIC ≥ 4 μg.ml-1 considered R [24].
Although susceptibility breakpoints have not yet been
established for amphotericin B and posaconazole, strains
with MIC ≤ 1 μg.ml-1 were considered susceptible [25,26].
Minimal fungicidal concentration (MFC) to all antifun-
gals was also determined. The content of each well con-
taining drug concentrations to and higher than the MIC,
and also the positive growth control were transferred to
Sabouraud dextrose agar plates and incubated at 35°C for
48 h, as previously described [27]. The MFC was the low-
est drug concentration that killed ≥ 99% of the final inoc-
ulum.
For Aspergillus spp., the CLSI protocol M 38-A was used to
determine MIC values of voriconazole, posaconazole,
itraconazole and amphotericin B (all antifungals tested
concentration ranged 0.03–16 μg.ml-1) [28]. Although the
unavailability of breakpoints for Aspergillus  species, we
followed several researchers that consider values of MIC ≤
1 μg.ml-1 as susceptible [29,30]. MFC values were deter-
mined, as previously described [31], and defined as the
lowest drug concentration that showed either no growth
or fewer than three colonies to obtain approximately 99 to
99.5% killing activity.
The susceptibility tests to the antifungals mentioned
above were repeated in the presence of the propofol infu-
sion or its vehicle in three distinct concentrations (1.25,
2.5 and 5 mg.ml-1). Since propofol infusion and its vehi-
cle are opaque solutions, making impossible MIC deter-
mination, the content of each well containing antifungal
+ propofol drugs was cultured for MFC determination and
values compared with the MFC to antifungals alone.
Flow cytometry analysis
Yeast cells were incubated at 150 rpm, overnight, until late
exponential growth, in Sabouraud broth (Difco) at 37°C.
Yeasts cells were harvested after centrifugation and a 1 ×
106 cells.ml-1 suspension was prepared in PBS supple-
mented with 2% glucose (GH solution) and later divided
into aliquots of 1 ml. The cells were then incubated with
different concentrations of propofol infusion (0, 1.25, 2.5
and 5 mg.ml-1) at 37°C for 90 minutes and afterwards
washed thrice, ressuspended in sterile water supple-
mented with 2% glucose and stained with 0.5 μM FUN1
(Molecular Probes, Europe BV, Leiden, Holland) for 30
minutes at 37°C. A Beckman Coulter XL-MCL flow
cytometer (Beckman-Coulter Corp., Hialeah, FL, USA)
equipped with a 15 nm argon laser was used. From each
suspension 30000–50000 cells were analysed. The inten-
sity of fluorescence emitted by cells treated with propofol
infusion was determined at FL2 (575 nm) and compared
with non-treated cells (control). In parallel experiments,
yeast cells were treated with 0.1 mM sodium azide during
30 minutes, prior to incubation with propofol, as previ-
ously described [16], in order to block efflux pumps;
thereafter, the same flow cytometry analytical protocol
was used.BMC Microbiology 2008, 8:9 http://www.biomedcentral.com/1471-2180/8/9
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Intracellular accumulation of [3H]-labelled itraconazole
Candida cells were initially incubated under similar condi-
tions as previously described for flow cytometry assays.
The cells were harvested by centrifugation at 5000 rpm for
10 minutes at 4°C, washed thrice, ressuspended in PBS at
a final concentration of 2.5 × 108 cells.ml-1 and incubated
with 0, 1.25 and 5 mg.ml-1 of propofol infusion at 37°C,
with continuous shaking at 300 rpm for 30 minutes [16].
Parallel experiments were prepared, but also involving a
pre-incubation of the yeasts cells with sodium azide at 0.1
mM. The cells were washed thrice and [3H]-labelled itra-
conazole was added to yeast suspensions at a final con-
centration of 3 μM, as previously described[16]; the cells
were incubated in glass vials at 37°C, with continuous
shaking (300 rpm), during 1 hour and then harvested by
centrifugation at 5000 rpm for 10 min at 4°C, washed
thrice with 3 ml of ice-cold PBS containing 10 μM unla-
belled itraconazole. The pellets were later ressuspended in
500 μl of PBS and the radioactivity was determined, fol-
lowing the addition of a scintillation cocktail (Optiphase
"Hiphase3", Perkin-Elmer), in a liquid scintillation coun-
ter (LKB Wallac, 1209 RackBeta).
Lipidic vehicle experiments
All the described experiments were repeated in the pres-
ence of the propofol lipidic vehicle used in Fresenius® for-
mulation (soya bean oil, egg lecithin, glycerol, sodium
hydroxide and sterile water).
Statistical analysis
The effects of different concentrations of propofol upon
germination of fungal cells and MFC values of the distinct
antifungals were compared using one-way analysis of var-
iance (ANOVA) and Student's t-test. Significance was
accepted at p < 0.05. The SPSS 14.0 program for Windows
was used to perform the statistical analysis. All susceptibil-
ity experiments were run in duplicate and growth and
radioactivity assays in triplicate.
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